Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly and Novartis put VC cash into Aeglea's series B

This article was originally published in Scrip

Executive Summary

Aeglea Biotherapeutics (Austin, TX), focused on treating inborn errors of metabolism and therapies targeting tumor metabolism, has raised $44m in series B financing led by existing investors Lilly Ventures and Novartis Venture Fund with participation by UT Horizon Fund and new investors, including OrbiMed, Jennison Associates, Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group and Cowen Investments. Aeglea's lead candidate, AEB1102 (optimized human Arginase I) is slated to enter Phase I/II later this year as an enzyme replacement therapy in patients with hyperargininemia (HA) caused by Arginase I deficiency. Left untreated, HA may lead to spasticity, loss of ambulation and severe intellectual disability, and there is currently no effective therapy to treat the underlying cause of HA. Aeglea is also planning Phase I development for AEB1102 in oncology, targeting abnormal tumor metabolism characterized by arginine dependence. Aeglea was founded in 2013 with $12m in financing. It has three additional preclinical candidates: AEB4104, which degrades homocystine, for treating homocystinuria; and AEB3103, which degrades cysteine/cysteine and increase oxidative stress through glutathione depletion, and AEB2109, which degrades methionine, both for oncology applications.

You may also be interested in...

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts